ArticleOphthalmic research2025
Effect of Estimated Individual Vitreous Volume on Intraocular Pressure Spikes after Intravitreal Anti-Vascular Endothelial Growth Factors Injection.
Article in Ophthalmic research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Real-World Validation of the VIVEX Formula for Vitreous Volume Estimation in Vitreoretinal Surgery: A First Clinical Case Series.Ophthalmology and therapy · 2026Article
- Measurement of Acute Intraocular Pressure Elevation Immediately After Intravitreal Anti-VEGF Injection and Analysis of Prefilled Syringe Accuracy.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Geometry-Based Intravitreal Pharmacokinetics: A Theoretical Pharmacokinetic Modeling Study Using Triamcinolone Acetonide and Vancomycin as Representative Intravitreal Agents.Clinical ophthalmology (Auckland, N.Z.) · 2026Article
- Dose adjustment of intravitreal medications and gases according to axial length and vitreous cavity volume.Arquivos brasileiros de oftalmologia · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThe present study aimed to evaluate the effect of estimated individual vitreous volume (VV) on intraocular pressure (IOP) spikes after intravitreal anti-vascular endothelial growth factor injections (IVIs).
methodsVVs of eyes were calculated using an axial length (AL)-based formula AL3 × (π/6) × 0.76 + 0.012 × (AL - 24), and study eyes were divided into four groups according to their VVs; <4.5 cm3 (Group 1, n = 52), 4.5-5.0 cm3 (Group 2, n = 60), 5.0-5.50 cm3 (Group 3, n = 60), and >5.50 cm3 (Group 4, n = 35). IOP measurements were taken Pre-IVI, immediately after (Post-IVI-0), 5 min (Post-IVI-5), 15 min (Post-IVI-15), and 30 min after the IVI.
resultsA significant IOP change was found between the five-time points in all groups (p < 0.001 for all). Regarding the same time point measurement comparison between the groups, only a statistically significant change was found in the Post-IVI-0 point (p = 0.001). In a post hoc analysis, Group 1, Group 2, and Group 3 had significantly higher IOP values when compared to Group 4 (p < 0.05 for all). Patients treated with prefilled ranibizumab syringes exhibited lower IOP increases than vial-prepared aflibercept injection at the Post-IVI-0 time point (p = 0.042).
conclusionsA similar increase in IOP was observed in eyes with low and intermediate volumes, but the increase was less pronounced in those with high volumes after the IVI. Prefilled syringe form showed a lower IOP increase tendency in comparison with vial-prepared forms of the molecules.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.